目的 觀察阿加曲班注射液對(duì)急性腦梗死患者的有效性和安全性。方法 2010年12月—2012年12月在中國人民解放軍第254醫(yī)院住院的急性腦梗死患者60例隨機(jī)分為治療組（30例）和對(duì)照組（30例），兩組患者均給予降脂、調(diào)控血壓、控制血糖等對(duì)癥支持治療，對(duì)照組在此基礎(chǔ)上口服阿司匹林片，1 片/次，1 次/d；治療組給予阿加曲班注射液，第1、2天每天用阿加曲班注射液60 mg，以500 mL生理鹽水稀釋，24 h持續(xù)靜脈滴注；其后5 d每天用阿加曲班注射液10 mg以250 mL生理鹽水稀釋，分早晚2次持續(xù)靜脈滴注，每次3 h，兩組均連續(xù)治療7 d。觀察、統(tǒng)計(jì)兩組患者治療7、14 d的NIHSS評(píng)分改善情況和不良反應(yīng)發(fā)生情況。結(jié)果 兩組治療后7、14 d與治療前比較NIHSS評(píng)分均明顯降低，差異有統(tǒng)計(jì)學(xué)意義（P＜0.05）；治療后，治療組較對(duì)照組降低更明顯，兩組差異有統(tǒng)計(jì)學(xué)意義（P＜0.05）。治療組與對(duì)照組總有效率分別為93.3%、76.7%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P＜0.05）。兩組患者均無嚴(yán)重不良反應(yīng)發(fā)生。結(jié)論 阿加曲班注射液對(duì)急性腦梗死有較好的治療效果，且無不良反應(yīng)發(fā)生。

Objective To evaluate the efficacy and safety of Argatroban Injection in the treatment of the patients with acute cerebral infarction. Methods The patients (60 cases) diagnosed as acutecerebral infarction in Chinese PLA 254 Hospital from December 2010 to December 2012 were randomly divided into treatment (30 cases) and control (30 cases) groups. The two groups were given the treatment to reduce blood fat, and control blood pressure and sugar. In addition, the patients in the control group was po administered with Aspirin, 1 pill/time, once daily. The treatment group was treated with Argatroban Injection (60 mg diluted with 500 mL physiological saline) through 24 h continuous iv pump infusion on the first 2 d. The next 5 d they were treated with Argatroban Injection (10 mg diluted with 250 mL physiological saline), through continuous 3 h iv infusion twice daily in the morning and evening. The patients in the two groups were treated for 7 d. NIHSS scoring and adverse reactions were observed and evaluated after the treatment for 7 d and 14 d, at the same time. Results Within 7 d and 14 d after the treatment, the NIHSS scores of the patient in the two groups were significantly lower than those before the treatment (P < 0.05), and the difference between the two groups was statistically significant (P < 0.05). The efficiency for the patients both in the treatment and control groups were 93.3% and 76.7% with the significant difference (P < 0.05). There was no adverse reaction in the two groups. Conclusion Argatroban Injection has an accurate curative effect on the progressive cerebral infarction, but has no adverse reaction.